However, there were no objective responses to FGFR inhibitor AZD4547 in the tumor-agnostic NCI-MATCH study, nor were there any patients with a progression-free survival duration of 6 months or longer among the 17 patients with FGFR1 amplification and the 3 with FGFR2 amplification treated with AZD454745. Here, FGFR2 is linked to neoplasm.